# SMAD6

## Overview
SMAD6 is a gene that encodes the protein SMAD family member 6, which is a member of the inhibitory SMAD (I-SMAD) family. This protein plays a pivotal role in the regulation of the bone morphogenetic protein (BMP) and transforming growth factor-beta (TGF-β) signaling pathways. As an inhibitory SMAD, SMAD6 functions primarily as a negative regulator, modulating cellular processes such as differentiation, tissue formation, and apoptosis by preventing the activation of downstream signaling components. The protein is characterized by its MH1 and MH2 domains, which are essential for its DNA binding and protein-protein interaction capabilities, respectively (Hariharan2008Structure–function; Calpena2020SMAD6). SMAD6's regulatory actions are crucial for maintaining cellular homeostasis and have significant implications in various developmental and pathological conditions, including congenital heart disease and craniosynostosis, when mutated (Li2024Deamidation; Timberlake2016Two).

## Structure
SMAD6 is a protein composed of 496 amino acids and features two highly conserved domains: the MH1 and MH2 domains. The MH1 domain is involved in DNA binding, although it lacks the specific DNA-binding beta-hairpin motif found in receptor-regulated Smads (R-Smads). Instead, it contains a basic patch formed by a longer L1 loop with four arginines, which may contribute to its weak DNA binding ability (Hariharan2008Structure–function). The MH2 domain is crucial for protein-protein interactions and is essential for the inhibitory function of SMAD6 on TGFβ/BMP signaling (Calpena2020SMAD6; Attisano2001Thesmads).

Structurally, the MH2 domain of SMAD6 includes a central beta sandwich, a three-helix bundle, and a loop-helix region. It has a conserved helix H1, a shortened helix H2, and lacks helix H4. The domain also features two additional short beta strands, B10' and B10'', inserted between the conserved B10 and B11 strands (Hariharan2008Structure–function). SMAD6 does not have the carboxy-terminal SSXS motif, which is a receptor phosphorylation site found in other Smads (Hata1998Smad6). The protein's structural flexibility, particularly in the MH2 domain, contributes to its specific inhibitory role in BMP signaling (Hariharan2008Structure–function).

## Function
SMAD6 is an inhibitory SMAD protein that plays a crucial role in regulating signaling pathways in healthy human cells. It primarily functions as a negative regulator of the bone morphogenetic protein (BMP) signaling pathway by competing with SMAD4 for binding to receptor-activated SMAD1, forming an inactive SMAD1-SMAD6 complex. This action prevents the formation of the SMAD1-SMAD4 complex necessary for BMP signaling, thereby modulating cellular processes such as differentiation and tissue formation (Hata1998Smad6).

In addition to its role in BMP signaling, SMAD6 is involved in the negative regulation of noncanonical TGF-β1 signaling pathways. It inhibits the TGF-β1-induced activation of the TRAF6-TAK1-p38 MAPK/JNK pathway by recruiting the deubiquitinating enzyme A20 to TRAF6. This recruitment prevents K63-linked polyubiquitination of TRAF6, thereby reducing the phosphorylation of TAK1 and p38 MAPK/JNK, which are important for cellular functions such as apoptosis (Jung2013Smad6). SMAD6's regulatory actions are crucial for maintaining cellular homeostasis and preventing excessive apoptotic responses, which are important for tissue homeostasis and the prevention of diseases like cancer (Jung2013Smad6).

## Clinical Significance
Mutations in the SMAD6 gene are associated with several congenital and developmental disorders. Pathogenic variants of SMAD6 have been linked to congenital heart disease (CHD), craniosynostosis (CRS), and cardiovascular malformations (CVM). These conditions are often related to disruptions in the bone morphogenetic protein (BMP) signaling pathway, which SMAD6 normally inhibits (Li2024Deamidation). 

In particular, SMAD6 mutations have been implicated in bicuspid aortic valve (BAV) and thoracic aortic aneurysm (TAA), with studies indicating that these mutations can lead to haploinsufficiency, affecting the gene's ability to regulate BMP and transforming growth factor (TGF)-β signaling pathways (Gillis2017Candidate; Luyckx2019Confirmation). 

Craniosynostosis, characterized by the premature fusion of skull bones, has also been associated with SMAD6 mutations. The presence of a common variant near the BMP2 gene can significantly increase the risk of craniosynostosis in individuals with SMAD6 mutations, supporting a two-locus model of inheritance (Timberlake2016Two; Calpena2020SMAD6). 

Overall, SMAD6 mutations contribute to a spectrum of conditions by altering its normal inhibitory role in critical signaling pathways, leading to developmental abnormalities.

## Interactions
SMAD6 is known to interact with various proteins and nucleic acids, playing a significant role in modulating signaling pathways. It competes with the Smad4 tumor suppressor for binding to receptor-activated Smad1, forming an inactive Smad1-Smad6 complex, which inhibits BMP/Smad1 signaling without affecting the phosphorylation of Smad1 (Hata1998Smad6). SMAD6 specifically interacts with Smad1 but not with Smad2, indicating a selective inhibition of BMP signaling pathways (Hata1998Smad6).

In the nucleus, SMAD6 functions as a transcriptional co-repressor by interacting with histone deacetylases (HDACs), particularly class I HDACs such as HDAC-1 and HDAC-3. This interaction is crucial for the regulation of gene transcription, as it involves the modification of chromatin conformation (Bai2002A). SMAD6 also interacts with homeobox proteins like Hoxc-8, forming a transcriptional complex that contributes to transcriptional repression (Bai2002A).

SMAD6 is phosphorylated by Protein kinase X (PrKX), which is essential for its role in HL-60 cell differentiation into macrophages. This phosphorylation occurs at serine residues and is crucial for SMAD6's function as a transcriptional regulator during cell differentiation (Glesne2006Smad6).


## References


[1. (Gillis2017Candidate) Elisabeth Gillis, Ajay A. Kumar, Ilse Luyckx, Christoph Preuss, Elyssa Cannaerts, Gerarda van de Beek, Björn Wieschendorf, Maaike Alaerts, Nikhita Bolar, Geert Vandeweyer, Josephina Meester, Florian Wünnemann, Russell A. Gould, Rustam Zhurayev, Dmytro Zerbino, Salah A. Mohamed, Seema Mital, Luc Mertens, Hanna M. Björck, Anders Franco-Cereceda, Andrew S. McCallion, Lut Van Laer, Judith M. A. Verhagen, Ingrid M. B. H. van de Laar, Marja W. Wessels, Emmanuel Messas, Guillaume Goudot, Michaela Nemcikova, Alice Krebsova, Marlies Kempers, Simone Salemink, Toon Duijnhouwer, Xavier Jeunemaitre, Juliette Albuisson, Per Eriksson, Gregor Andelfinger, Harry C. Dietz, Aline Verstraeten, and Bart L. Loeys. Candidate gene resequencing in a large bicuspid aortic valve-associated thoracic aortic aneurysm cohort: smad6 as an important contributor. Frontiers in Physiology, June 2017. URL: http://dx.doi.org/10.3389/fphys.2017.00400, doi:10.3389/fphys.2017.00400. This article has 79 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphys.2017.00400)

[2. (Bai2002A) Shuting Bai and Xu Cao. A nuclear antagonistic mechanism of inhibitory smads in transforming growth factor-β signaling. Journal of Biological Chemistry, 277(6):4176–4182, February 2002. URL: http://dx.doi.org/10.1074/jbc.m105105200, doi:10.1074/jbc.m105105200. This article has 91 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m105105200)

[3. (Timberlake2016Two) Andrew T Timberlake, Jungmin Choi, Samir Zaidi, Qiongshi Lu, Carol Nelson-Williams, Eric D Brooks, Kaya Bilguvar, Irina Tikhonova, Shrikant Mane, Jenny F Yang, Rajendra Sawh-Martinez, Sarah Persing, Elizabeth G Zellner, Erin Loring, Carolyn Chuang, Amy Galm, Peter W Hashim, Derek M Steinbacher, Michael L DiLuna, Charles C Duncan, Kevin A Pelphrey, Hongyu Zhao, John A Persing, and Richard P Lifton. Two locus inheritance of non-syndromic midline craniosynostosis via rare smad6 and common bmp2 alleles. eLife, September 2016. URL: http://dx.doi.org/10.7554/elife.20125, doi:10.7554/elife.20125. This article has 186 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.20125)

[4. (Jung2013Smad6) Su Myung Jung, Ji-Hyung Lee, Jinyoung Park, Young Sun Oh, Sung Kyun Lee, Jin Seok Park, Youn Sook Lee, Jun Hwan Kim, Jae Young Lee, Yoe-Sik Bae, Seung-Hoi Koo, Seong-Jin Kim, and Seok Hee Park. Smad6 inhibits non-canonical tgf-β1 signalling by recruiting the deubiquitinase a20 to traf6. Nature Communications, October 2013. URL: http://dx.doi.org/10.1038/ncomms3562, doi:10.1038/ncomms3562. This article has 85 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms3562)

[5. (Hariharan2008Structure–function) Ramkumar Hariharan and M. Radhakrishna Pillai. Structure–function relationship of inhibitory smads: structural flexibility contributes to functional divergence. Proteins: Structure, Function, and Bioinformatics, 71(4):1853–1862, January 2008. URL: http://dx.doi.org/10.1002/prot.21869, doi:10.1002/prot.21869. This article has 18 citations.](https://doi.org/10.1002/prot.21869)

[6. (Luyckx2019Confirmation) Ilse Luyckx, Gretchen MacCarrick, Marlies Kempers, Josephina Meester, Céline Geryl, Olivier Rombouts, Nils Peeters, Charlotte Claes, Nele Boeckx, Natzi Sakalihasan, Adeline Jacquinet, Alexander Hoischen, Geert Vandeweyer, Sarah Van Lent, Johan Saenen, Emeline Van Craenenbroeck, Janneke Timmermans, Anthonie Duijnhouwer, Harry Dietz, Lut Van Laer, Bart Loeys, and Aline Verstraeten. Confirmation of the role of pathogenic smad6 variants in bicuspid aortic valve-related aortopathy. European Journal of Human Genetics, 27(7):1044–1053, February 2019. URL: http://dx.doi.org/10.1038/s41431-019-0363-z, doi:10.1038/s41431-019-0363-z. This article has 33 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41431-019-0363-z)

[7. (Glesne2006Smad6) D Glesne and E Huberman. Smad6 is a protein kinase x phosphorylation substrate and is required for hl-60 cell differentiation. Oncogene, 25(29):4086–4098, February 2006. URL: http://dx.doi.org/10.1038/sj.onc.1209436, doi:10.1038/sj.onc.1209436. This article has 25 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1209436)

[8. (Hata1998Smad6) Akiko Hata, Giorgio Lagna, Joan Massagué, and Ali Hemmati-Brivanlou. Smad6 inhibits bmp/smad1 signaling by specifically competing with the smad4 tumor suppressor. Genes &amp; Development, 12(2):186–197, January 1998. URL: http://dx.doi.org/10.1101/gad.12.2.186, doi:10.1101/gad.12.2.186. This article has 559 citations.](https://doi.org/10.1101/gad.12.2.186)

[9. (Calpena2020SMAD6) Eduardo Calpena, Araceli Cuellar, Krithi Bala, Sigrid M.A. Swagemakers, Nils Koelling, Simon J. McGowan, Julie M. Phipps, Meena Balasubramanian, Michael L. Cunningham, Sofia Douzgou, Wanda Lattanzi, Jenny E.V. Morton, Deborah Shears, Astrid Weber, Louise C. Wilson, Helen Lord, Tracy Lester, David Johnson, Steven A. Wall, Stephen R.F. Twigg, Irene M.J. Mathijssen, Freya Boardman-Pretty, Simeon A. Boyadjiev, and Andrew O.M. Wilkie. Smad6 variants in craniosynostosis: genotype and phenotype evaluation. Genetics in Medicine, 22(9):1498–1506, September 2020. URL: http://dx.doi.org/10.1038/s41436-020-0817-2, doi:10.1038/s41436-020-0817-2. This article has 32 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41436-020-0817-2)

[10. (Attisano2001Thesmads) Liliana Attisano and Si Tuen Lee-Hoeflich. The smads. Genome Biology, 2(8):reviews3010.1, 2001. URL: http://dx.doi.org/10.1186/gb-2001-2-8-reviews3010, doi:10.1186/gb-2001-2-8-reviews3010. This article has 295 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/gb-2001-2-8-reviews3010)

[11. (Li2024Deamidation) Ling Li, Lei Lu, Ziqi Xiao, Jingyi Lv, Hefeng Huang, Bo Wu, Tongjin Zhao, Chengtao Li, Weimin Wang, and Hongyan Wang. Deamidation enables pathogenic smad6 variants to activate the bmp signaling pathway. Science China Life Sciences, 67(9):1915–1927, June 2024. URL: http://dx.doi.org/10.1007/s11427-023-2532-5, doi:10.1007/s11427-023-2532-5. This article has 0 citations.](https://doi.org/10.1007/s11427-023-2532-5)